Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220249557Vaccine and Uses thereof in Cell Therapy
US 11.08.2022
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No 17592601 Applicant Innovative Cellular Therapeutics Holdings, Ltd. Inventor Yang Li

The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFNγ.

2.20220249575FORMULATION AND TREATMENT FOR OPHTHALMIC DISORDERS
US 11.08.2022
Int.Class A61K 35/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
48Reproductive organs
51Umbilical cord; Umbilical cord blood; Umbilical stem cells
Appl.No 17394628 Applicant AVAV LABS LLC Inventor Philipp R. VITTI

The disclosure provides therapeutic ophthalmic formulations, kits, and uses thereof in the treatment of eye pathologies.

3.WO/2022/166913MODIFIED RED BLOOD CELLS AND USES THEREOF FOR TREATING HYPERURICEMIA AND GOUT
WO 11.08.2022
Int.Class C12N 5/078
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
Appl.No PCT/CN2022/075140 Applicant WESTLAKE THERAPEUTICS (HANGZHOU) CO. LIMITED Inventor GAO, Xiaofei
Provided are a red blood cell (RBC) having an agent linked thereto, wherein the agent is linked to at least one endogenous, non-engineered membrane protein of the RBC by by a sortase-mediated glycine conjugation or lysine side chain e-amino group conjugation, and wherein the agent comprises a uric acid degrading polypeptide, a uric acid transporter or the combination; a method for preparing the RBC; and the use of the RBC for preventing or treating a disorder, condition or disease associated with an elevated uric acid level including hyperuricemia or gout.
4.WO/2022/170093COMPOSITIONS AND METHODS FOR TREATING WITH CAR CELLS
WO 11.08.2022
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No PCT/US2022/015307 Applicant UNIVERSITY OF UTAH RESEARCH FOUNDATION Inventor ATANACKOVIC, Djordje
Disclosed are CAR polypeptides comprising a target specific receptor and a death domain. Disclosed are CAR polypeptides comprising a LINGO 1 antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Disclosed are CAR cells comprising one or more of the disclosed CAR polypeptides. Disclosed are cells comprising an altered α4β1 integrin. Disclosed are methods of treating comprising administering one or more of the disclosed cells to a subject in need thereof.
5.WO/2022/169283COMPOSITION COMPRISING LACTOBACILLUS PLANTARUM-DERIVED POLYSACCHARIDE OR EXTRACT
WO 11.08.2022
Int.Class C12P 19/04
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
Appl.No PCT/KR2022/001731 Applicant NEOREGEN BIOTECH Inventor SEO, Jeong Min
The present invention relates to a composition comprising Lactobacillus plantarum-derived polysaccharide or extract and, more specifically, by comprising Lactobacillus plantarum-derived polysaccharide or a Lactobacillus plantarum extract, may exhibit inflammatory inhibition, adipogenesis inhibition, intracellular glucose absorption inhibition, insulin resistance reduction and hepatic steatosis reduction effects, and may exhibit effects of treating or preventing a metabolic disease.
6.WO/2022/169943CELL CLUSTERS COMPRISING STEM AND ISLET CELLS, METHODS OF MAKING, AND TREATMENT OF DIABETES MELLITUS THEREWITH
WO 11.08.2022
Int.Class C08L 29/02
CCHEMISTRY; METALLURGY
08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
29Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal, or ketal radical; Compositions of hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers
02Homopolymers or copolymers of unsaturated alcohols
Appl.No PCT/US2022/015066 Applicant SYMBIOCELLTECH, LLC Inventor WESTENFELDER, Christof
Provided are compositions and methods of treating impaired glucose tolerance which substantially increase the islet donor pool and safety as well as remove the need for anti-rejections drugs. Described are methods of making cell clusters comprising: expanding pancreatic islet cells; and forming cell clusters comprising: the expanded islet cells and mesenchymal/adipose stem cells. Expansion of the islet cells may include => five population doublings. The islet cells may be primary islet cells obtained from an adult, non-diabetic donor having a North America Islet Donor Score (NAIDS) of < 80. Described are cell clusters produced by the methods. Additionally, methods of treatment by intraperitoneal administration of islet-sized cell clusters composed of high numbers of mesenchymal stem cells and expanded pancreatic islet cells, durably and reversibly treats, without hypoglycemia, both streptozotocin-induced and spontaneous Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, and other types of insulin-dependent diabetes mellitus, or impaired glucose tolerance.
7.20220249767METHOD FOR TREATMENT OF NEUROCOGNITIVE DECLINE
US 11.08.2022
Int.Class A61M 5/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
5Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
Appl.No 17592723 Applicant INVICTUS HEALTH, INC. Inventor Jeffrey I. Haugland

A method for treating a patient with a neurodegenerative disease including performing Ketamine Infusion Therapy on the patient, performing hyperbaric oxygen therapy on the patient, intranasally infusing plasma into the patient, and intranasally infusing diluted insulin into the patient. Performing hyperbaric oxygen therapy on the patient may include placing the patient into a hyperbaric chamber, sealing and pressurizing the hyperbaric chamber, and pumping oxygen into the hyperbaric chamber while it is pressurized. Before intranasally infusing plasma into the patient, the method may include drawing blood from the patient and centrifugally extracting the plasma from the drawn blood, such as platelet rich plasma (PRP). Before drawing blood from the patient, the method may include intravenously injecting the patient with supplements, such as a combination of magnesium, calcium, B-vitamins, Vitamin C, nicotinamide adenine dinucleotide (NAD+), and Glutathione.

8.20220249556METHODS FOR TRANSDUCING IMMUNE CELLS
US 11.08.2022
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No 17587138 Applicant Allogene Therapeutics, Inc. Inventor Todd LUMAN

Provided herein are improved methods for transducing immune cells, such as T cells, with retroviral vectors to express exogenous gene products, such as chimeric antigen receptors (CARs). Provided herein are methods that increase transduction efficiency thereby increasing the percentage of immune cells in a population expressing the exogenous gene product. Associated cells, cell populations, compositions and methods of use are also provided.

9.20220249563ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
US 11.08.2022
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No 17618642 Applicant Nanjing Legend Biotech Co., Ltd. Inventor Tao Zhao

Provided herein are anti-DLL3 chimeric antigen receptors (CARs), DLL3 binding proteins and uses of such CARs or DLL3 binding proteins in the treatment of DLL3 associated disorders, such as small cell lung cancer.

10.20220249573CARTILAGE REGENERATION USING CHONDROCYTE AND TGF-BETA
US 11.08.2022
Int.Class A61K 35/32
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
32Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
Appl.No 17488785 Applicant KOLON TISSUEGENE, INC. Inventor Moon Jong NOH

The present application is directed to a method of treating osteoarthritis, which includes obtaining a member of a transforming growth factor superfamily of proteins; obtaining a population of cultured mammalian cells that may contain vector encoding a gene, or a population of cultured connective tissue cells that do not contain any vector encoding a gene; and then transferring the protein and the connective tissue cells into an arthritic joint space of a mammalian host, such that the activity of the combination within the joint space results in regenerating connective tissue.